Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Kingchem
301509
5
Hunan Er-kang Pharmaceutical
300267
US Stock MarketDetailed Quotes
AGIO Agios Pharmaceuticals
- 28.610
- +0.240+0.85%
Trading Apr 24 12:27 ET
1.64BMarket Cap2.46P/E (TTM)
28.820High28.040Low92.01KVolume28.300Open28.370Pre Close2.63MTurnover0.18%Turnover Ratio2.46P/E (Static)57.30MShares62.58052wk High1.06P/B1.45BFloat Cap23.41552wk Low--Dividend TTM50.71MShs Float138.850Historical High--Div YieldTTM2.75%Amplitude15.770Historical Low28.558Avg Price1Lot Size
About Agios Pharmaceuticals Company
Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular metabolism and classical hematology. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.
Company Profile
SymbolAGIO
Company NameAgios Pharmaceuticals
Listing DateJul 24, 2013
Issue Price18.00
Founded2007
CEOMr. Brian Goff
MarketNASDAQ
Employees488
Fiscal Year Ends12-31
Address88 Sidney Street
CityCambridge
ProvinceMassachusetts
CountryUnited States of America
Zip Code02139-4169
Phone1-617-649-8600
Websitehttp://www.agios.com
Company Executives
- Name
- Position
- Salary
- Brian Goff
- Chief Executive Officer and Director
- 3.42M
- Tsveta Milanova
- Chief Commercial Officer
- 3.73M
- James William Burns
- Chief Legal Officer
- 1.93M
- Dr. Sarah Gheuens, M.D.,PhD
- Chief Medical Officer and Head of Research and Development
- 2.87M
- Cecilia Jones
- Chief Financial Officer
- 1.21M
- T. J. Washburn
- Principal Accounting Officer, Vice President and Controller
- --
- Dr. Jacqualyn A. Fouse, PhD
- Chairman of the Board
- 447.25K
- Kaye Foster
- Lead Independent Director
- 440.95K
- Cynthia Smith
- Independent Director
- 419.91K
- Catherine Owen
- Independent Director
- 659.94K
- Jeffrey D. Capello
- Independent Director
- 663.68K
- Dr. Rahul D. Ballal, PhD
- Independent Director
- 427.25K
- Dr. Maykin Ho, PhD
- Independent Director
- 424.75K
- Dr. David T. Scadden, M.D.
- Independent Director
- 429.75K
Market Insights
Discussing
Trade war escalates: What’s next for Chinese stocks?
🎙️Discussion 1. China-EU EV negotiations kick off recently. How do you think the negotiations will impact the performance of related stocks
Moo Earnings
Feb 17 19:21
Alibaba Q4 FY2024 Earnings Preview: Predict & Win Big! 🚀
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma
Moo Live
Mar 20 02:25
FOMC Press Conference, March 19, 2025
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now
Discussing
Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context,
Moo Live
Jan 23 16:54
MicroStrategy Q4 2024 earnings conference call